Literature DB >> 28379630

UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model.

Jake Wang1, Curtis J Perry2, Katrina Meeth1,3, Durga Thakral1, William Damsky1, Goran Micevic1,3, Susan Kaech2, Kim Blenman1, Marcus Bosenberg1,3.   

Abstract

Human melanomas exhibit relatively high somatic mutation burden compared to other malignancies. These somatic mutations may produce neoantigens that are recognized by the immune system, leading to an antitumor response. By irradiating a parental mouse melanoma cell line carrying three driver mutations with UVB and expanding a single-cell clone, we generated a mutagenized model that exhibits high somatic mutation burden. When inoculated at low cell numbers in immunocompetent C57BL/6J mice, YUMMER1.7 (Yale University Mouse Melanoma Exposed to Radiation) regresses after a brief period of growth. This regression phenotype is dependent on T cells as YUMMER1.7 tumors grow significantly faster in immunodeficient Rag1-/- mice and C57BL/6J mice depleted of CD4 and CD8 T cells. Interestingly, regression can be overcome by injecting higher cell numbers of YUMMER1.7, which results in tumors that grow without effective rejection. Mice that have previously rejected YUMMER1.7 tumors develop immunity against higher doses of YUMMER1.7 tumor challenge. In addition, escaping YUMMER1.7 tumors are sensitive to anti-CTLA-4 and anti-PD-1 therapy, establishing a new model for the evaluation of immune checkpoint inhibition and antitumor immune responses.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Braf; UV radiation; immunotherapy; melanoma; mouse models

Mesh:

Substances:

Year:  2017        PMID: 28379630      PMCID: PMC5820096          DOI: 10.1111/pcmr.12591

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  23 in total

Review 1.  The future of immune checkpoint therapy.

Authors:  Padmanee Sharma; James P Allison
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

Review 2.  Lost in translation: animal models and clinical trials in cancer treatment.

Authors:  Isabella Wy Mak; Nathan Evaniew; Michelle Ghert
Journal:  Am J Transl Res       Date:  2014-01-15       Impact factor: 4.060

Review 3.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

4.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

Review 5.  Mouse models for melanoma: a personal perspective.

Authors:  Jürgen C Becker; Roland Houben; David Schrama; Heike Voigt; Selma Ugurel; Ralph A Reisfeld
Journal:  Exp Dermatol       Date:  2009-10-22       Impact factor: 3.960

6.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

7.  The Genetic Evolution of Melanoma from Precursor Lesions.

Authors:  A Hunter Shain; Iwei Yeh; Ivanka Kovalyshyn; Aravindhan Sriharan; Eric Talevich; Alexander Gagnon; Reinhard Dummer; Jeffrey North; Laura Pincus; Beth Ruben; William Rickaby; Corrado D'Arrigo; Alistair Robson; Boris C Bastian
Journal:  N Engl J Med       Date:  2015-11-12       Impact factor: 91.245

8.  Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin.

Authors:  Iñigo Martincorena; Amit Roshan; Moritz Gerstung; Peter Ellis; Peter Van Loo; Stuart McLaren; David C Wedge; Anthony Fullam; Ludmil B Alexandrov; Jose M Tubio; Lucy Stebbings; Andrew Menzies; Sara Widaa; Michael R Stratton; Philip H Jones; Peter J Campbell
Journal:  Science       Date:  2015-05-22       Impact factor: 47.728

9.  The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations.

Authors:  Katrina Meeth; Jake Xiao Wang; Goran Micevic; William Damsky; Marcus W Bosenberg
Journal:  Pigment Cell Melanoma Res       Date:  2016-08-03       Impact factor: 4.693

10.  High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival.

Authors:  Daniel T Utzschneider; Francesca Alfei; Patrick Roelli; David Barras; Vijaykumar Chennupati; Stephanie Darbre; Mauro Delorenzi; Daniel D Pinschewer; Dietmar Zehn
Journal:  J Exp Med       Date:  2016-07-25       Impact factor: 14.307

View more
  56 in total

1.  Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors.

Authors:  Katie M Leick; Joel Pinczewski; Ileana S Mauldin; Samuel J Young; Donna H Deacon; Amber N Woods; Marcus W Bosenberg; Victor H Engelhard; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2019-05-27       Impact factor: 6.968

2.  PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity.

Authors:  Hyungsoo Kim; Heejung Kim; Yongmei Feng; Yan Li; Hironari Tamiya; Stefania Tocci; Ze'ev A Ronai
Journal:  Sci Transl Med       Date:  2020-07-08       Impact factor: 17.956

3.  Common germline variants of the human APOE gene modulate melanoma progression and survival.

Authors:  Benjamin N Ostendorf; Jana Bilanovic; Nneoma Adaku; Kimia N Tafreshian; Bernardo Tavora; Roger D Vaughan; Sohail F Tavazoie
Journal:  Nat Med       Date:  2020-05-25       Impact factor: 53.440

4.  Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses.

Authors:  Jennifer A Lo; Masayoshi Kawakubo; Vikram R Juneja; Mack Y Su; Tal H Erlich; Martin W LaFleur; Lajos V Kemeny; Mamunur Rashid; Mohsen Malehmir; S Alireza Rabi; Rumya Raghavan; Jennifer Allouche; Gyulnara Kasumova; Dennie T Frederick; Kristen E Pauken; Qing Yu Weng; Marcelo Pereira da Silva; Yu Xu; Anita A J van der Sande; Whitney Silkworth; Elisabeth Roider; Edward P Browne; David J Lieb; Belinda Wang; Levi A Garraway; Catherine J Wu; Keith T Flaherty; Constance E Brinckerhoff; David W Mullins; David J Adams; Nir Hacohen; Mai P Hoang; Genevieve M Boland; Gordon J Freeman; Arlene H Sharpe; Dieter Manstein; David E Fisher
Journal:  Sci Transl Med       Date:  2021-02-17       Impact factor: 17.956

5.  Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.

Authors:  Fan Huang; Christophe Gonçalves; Margarita Bartish; Joelle Rémy-Sarrazin; Mark E Issa; Brendan Cordeiro; Qianyu Guo; Audrey Emond; Mikhael Attias; William Yang; Dany Plourde; Jie Su; Marina Godoy Gimeno; Yao Zhan; Alba Galán; Tomasz Rzymski; Milena Mazan; Magdalena Masiejczyk; Jacek Faber; Elie Khoury; Alexandre Benoit; Natascha Gagnon; David Dankort; Fabrice Journe; Ghanem E Ghanem; Connie M Krawczyk; H Uri Saragovi; Ciriaco A Piccirillo; Nahum Sonenberg; Ivan Topisirovic; Christopher E Rudd; Wilson H Miller; Sonia V Del Rincón
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

6.  Pathology of spontaneous and immunotherapy-induced tumor regression in a murine model of melanoma.

Authors:  Kim R M Blenman; Jake Wang; Shawn Cowper; Marcus Bosenberg
Journal:  Pigment Cell Melanoma Res       Date:  2019-02-27       Impact factor: 4.693

7.  T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.

Authors:  Natalie J Neubert; Martina Schmittnaegel; Natacha Bordry; Sina Nassiri; Noémie Wald; Christophe Martignier; Laure Tillé; Krisztian Homicsko; William Damsky; Hélène Maby-El Hajjami; Irina Klaman; Esther Danenberg; Kalliopi Ioannidou; Lana Kandalaft; George Coukos; Sabine Hoves; Carola H Ries; Silvia A Fuertes Marraco; Periklis G Foukas; Michele De Palma; Daniel E Speiser
Journal:  Sci Transl Med       Date:  2018-04-11       Impact factor: 17.956

8.  Immune Cell and Cell Cluster Phenotyping, Quantitation, and Visualization Using In Silico Multiplexed Images and Tissue Cytometry.

Authors:  Kim R M Blenman; Marcus W Bosenberg
Journal:  Cytometry A       Date:  2018-11-23       Impact factor: 4.355

9.  Long-Term Programming of CD8 T Cell Immunity by Perinatal Exposure to Glucocorticoids.

Authors:  Jun Young Hong; Jaechul Lim; Fernando Carvalho; Jen Young Cho; Bharat Vaidyanathan; Shuang Yu; Charles Annicelli; W K Eddie Ip; Ruslan Medzhitov
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

Review 10.  Mouse Models for Cancer Immunotherapy Research.

Authors:  Brian Olson; Yadi Li; Yu Lin; Edison T Liu; Akash Patnaik
Journal:  Cancer Discov       Date:  2018-10-11       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.